Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. by Agnandji, ST et al.
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 374;17 nejm.org April 28, 2016 1647
The authors’ full names, academic de-
grees, and affiliations are listed in the Ap-
pendix. Address reprint requests to Dr. 
Addo at the University Medical Center 
Hamburg–Eppendorf, 1st Department of 
Medicine, Division of Tropical Medicine, 
Martinistr. 52, 20246 Hamburg, Germany, 
or at  m . addo@ uke . de; or to Dr. Siegrist 
at the Center for Vaccinology, Geneva 
University Hospitals and Faculty of Medi-
cine, Centre Medical Universitaire, 1 Rue 
Michel-Servet, 1211 Geneva 4, Switzer-
land, or at  claire-anne . siegrist@ unige . ch.
* The contributions of the authors, com-
mittee members, and other members of 
the VSV Ebola Consortium (VEBCON) 
are described in the Supplementary Ap-
pendix, available at NEJM.org.
Drs. Agnandji, Huttner, Zinser, Njuguna, 
Bejon, Kremsner, Addo, and Siegrist con-
tributed equally to this article.
A preliminary version of this article was 
published on April 1, 2015, at NEJM.org.
N Engl J Med 2016;374:1647-60.
DOI: 10.1056/NEJMoa1502924
Copyright © 2016 Massachusetts Medical Society.
BACKGROUND
The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine 
expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and im-
munogenicity testing before its use in West Africa.
METHODS
We performed three open-label, dose-escalation phase 1 trials and one randomized, 
double-blind, controlled phase 1 trial to assess the safety, side-effect profile, and im-
munogenicity of rVSV-ZEBOV at various doses in 158 healthy adults in Europe and 
Africa. All participants were injected with doses of vaccine ranging from 300,000 to 
50 million plaque-forming units (PFU) or placebo.
RESULTS
No serious vaccine-related adverse events were reported. Mild-to-moderate early-onset 
reactogenicity was frequent but transient (median, 1 day). Fever was observed in up to 
30% of vaccinees. Vaccine viremia was detected within 3 days in 123 of the 130 par-
ticipants (95%) receiving 3 million PFU or more; rVSV was not detected in saliva or 
urine. In the second week after injection, arthritis affecting one to four joints devel-
oped in 11 of 51 participants (22%) in Geneva, with pain lasting a median of 8 days 
(interquartile range, 4 to 87); 2 self-limited cases occurred in 60 participants (3%) in 
Hamburg, Germany, and Kilifi, Kenya. The virus was identified in one synovial-fluid 
aspirate and in skin vesicles of 2 other vaccinees, showing peripheral viral replication 
in the second week after immunization. ZEBOV-glycoprotein–specific antibody re-
sponses were detected in all the participants, with similar glycoprotein-binding anti-
body titers but significantly higher neutralizing antibody titers at higher doses. Glyco-
protein-binding antibody titers were sustained through 180 days in all participants.
CONCLUSIONS
In these studies, rVSV-ZEBOV was reactogenic but immunogenic after a single dose and 
warrants further evaluation for safety and efficacy. (Funded by the Wellcome Trust and 
others; ClinicalTrials.gov numbers, NCT02283099, NCT02287480, and NCT02296983; 
Pan African Clinical Trials Registry number, PACTR201411000919191.)
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In August 2014, after the outbreak of Ebola virus disease was declared a public health emergency of international concern 
by the World Health Organization (WHO), the 
Canadian government donated 800 vials of 
the replication-competent recombinant vesicular 
stomatitis virus (rVSV)–vectored Zaire ebolavirus 
(rVSV-ZEBOV) candidate vaccine to the WHO. 
The VSV Ebola Consortium (VEBCON) was cre-
ated under the auspices of the WHO to initiate 
phase 1 studies to facilitate rapid progression to 
phase 2 and 3 trials in affected countries.1
Live replicating viral vaccines elicit humoral 
and cellular immune responses against viral 
pathogens.2,3 A single injection of 10 million 
plaque-forming units (PFU) of rVSV-ZEBOV pro-
tected nonhuman primates exposed to lethal 
doses of ZEBOV.4-7 Vesicular stomatitis virus be-
longs to the Rhabdoviridae family.8 In livestock, 
wild-type VSV causes vesicles and ulcerations of 
the oral tissues, feet, and teats.9 Human infec-
tions are rare and asymptomatic or typically 
cause mild influenza-like illness, although more 
severe infections have been described.9-14 The 
wild-type virus is not endemic in Africa and 
Europe.15,16 The preclinical safety record of the 
rVSV vector is encouraging: among approximately 
80 immunized nonhuman primates, none had 
detectable toxic effects.3 Viremia associated with 
rVSV-ZEBOV was detected on day 2 only, sug-
gesting rapid viral clearance through the innate 
immune response. Safety in immunocompro-
mised hosts was assessed in a few nonhuman 
primates infected with the human immunodefi-
ciency virus6 and in mice with severe combined 
immunodeficiency.17 None of the animals had 
detectable illness after immunization. Viral shed-
ding in saliva and urine was not observed.3
To assess the safety and immunogenicity of 
various doses of rVSV-ZEBOV in countries with or 
without previous outbreaks of Ebola virus dis-
ease, we initiated parallel, harmonized VEBCON 
trials in Lambaréné, Gabon; Kilifi, Kenya; Ham-
burg, Germany; and Geneva, Switzerland. We re-
port the 6-month safety and immunogenicity 
data from these ongoing studies.
Me thods
Study Designs and Participants
The studies in Lambaréné, Kilifi, and Hamburg 
were open-label, uncontrolled, phase 1 trials 
designed to assess the safety, side-effect pro-
files, and immunogenicity of ascending doses of 
rVSV-ZEBOV vaccine (BPSC1001) at doses rang-
ing from 300,000 to 20 million PFU in healthy 
adults of both sexes between the ages of 18 and 
55 years. The Geneva study was a double-blind, 
randomized, placebo-controlled, phase 1 trial 
assessing the safety and immunogenicity of the 
rVSV–ZEBOV vaccine at doses of 10 million and 
50 million PFU in healthy adults between the 
ages of 18 and 65 years. Full details regarding 
the study centers, entry criteria, and procedures 
are provided in the study protocol, available with 
the full text of this article at NEJM.org. The stud-
ies were reviewed and approved by the respective 
national competent authorities, local ethics com-
mittees, the German authority for genetic engi-
neering, and the WHO research ethics review 
committee. All the participants provided written 
informed consent. An independent consortium-
wide data and safety monitoring board provided 
oversight.
All four studies were investigator-initiated 
trials sponsored by each local institution. The 
Wellcome Trust provided funding through a 
grant to the WHO. A total of 800 vaccine doses 
were donated to the WHO by the Public Health 
Agency of Canada. Funding bodies and the vac-
cine manufacturers were not involved in the 
analysis of the data, nor did they contribute to 
the preparation or writing of the manuscript.
Vaccine and Placebo
The rVSV-ZEBOV vaccine was developed by the 
Canadian National Microbiology Laboratory and 
was licensed to BioProtection Systems (a subsid-
iary of NewLink Genetics). The vaccine was sub-
sequently sublicensed to Merck, which has as-
sumed responsibility for ongoing research and 
development. The vaccine was manufactured at 
IDT Biologika in Dessau-Rosslau, Germany, and 
stored in a manner consistent with good manu-
facturing practices. The same lot (no. 003 05 13), 
which was dispensed in single-dose vials as 100 
million PFU per milliliter, was sent from Canada 
to Geneva and subsequently to the other sites. 
(Additional details regarding reconstitution are 
provided in the Supplementary Appendix.) Pla-
cebo syringes containing 0.5 ml of saline were 
packaged identically.
Vaccination
Injections were administered intramuscularly 
into the deltoid. Dose-escalation studies were 
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staggered (for details, see the Methods section 
in the Supplementary Appendix). In the Lam-
baréné cohort, participants received doses of 
300,000 or 3 million PFU. In Hamburg, partici-
pants received doses of 3 million or 20 million 
PFU. In Kilifi, participants received doses of 
3 million or 20 million PFU. In Geneva, the first 
19 run-in participants received a single open-label 
injection of 10 million PFU and were observed 
for at least 1 week. Thereafter, participants who 
were planning to deploy to Ebola-affected re-
gions were randomly assigned in a 1:1 ratio in a 
double-blind fashion to receive a vaccine dose of 
either 10 million or 50 million PFU, whereas 
those who were not planning to deploy to such 
regions were randomly assigned in a 1:1:1 ratio 
to receive either one of the vaccine doses or pla-
cebo. (An overview of the four trials is provided 
in Fig. S4 in the Supplementary Appendix.)
Safety Monitoring
Injection-site and systemic reactogenicity and 
medication use were recorded for 7 days after in-
jection and at follow-up (days 14 and 28). Clini-
cal and laboratory evaluations were performed 
during each study visit (for details, see the Meth-
ods section in the Supplementary Appendix). 
Laboratory analyses included a complete blood 
count and measurements of creatinine, C-reac-
tive protein, and liver function. Adverse events 
were listed for each participant according to the 
Common Terminology Criteria for Adverse Events 
and the Medical Dictionary for Regulatory Activities 
and are reported individually and in aggregate.
Investigation of Arthritis and Skin Lesions
After the observation of arthralgia in some 
Geneva participants, all but the first partici-
pant with swollen joints or axial involvement in 
Geneva underwent joint imaging by means of 
ultrasonography or magnetic resonance imaging 
(MRI), and all but two participants were referred 
to a rheumatologist. Arthritis was confirmed if 
the study team observed swelling or imaging 
revealed effusion. Participants in Geneva who 
had skin lesions underwent biopsy, swabbing, or 
puncture of lesions.
Detection of rVSV
We developed quantitative reverse-transcrip-
tase–polymerase-chain-reaction (RT-PCR) assays 
(TaqMan) targeting the VSV nucleoprotein gene 
(see the Methods section in the Supplementary 
Appendix). Results are expressed in copies per 
milliliter. In the dose-escalation trials, rVSV viral 
loads were monitored from day 0 to day 28 and 
included daily sampling of plasma, urine, and 
saliva through day 7 in Hamburg. In Lambaréné 
and Kilifi, total RNA from plasma, urine (400 μl), 
and saliva (200 μl) (Viral Transport Kit, BD) was 
stored in TRIzol LS Reagent (Life Technologies) 
and analyzed at St. George’s University of Lon-
don. In Hamburg, samples were assessed on site. 
In Geneva, RT-PCR was performed on days 1, 3, 
and 7 on all plasma specimens, on saliva and 
urine in the first 20 participants vaccinated with 
10 million PFU and 10 participants vaccinated 
with 50 million PFU, and later on skin vesicles 
and synovial fluid. RT-PCR assay to detect rVSV 
was performed on oral lesions observed in Ham-
burg and Geneva. Virus isolation was performed 
in Geneva by means of plaque assay on Vero E6 
cells from selected samples and confirmed on 
PCR and immunostaining (see the Methods sec-
tion in the Supplementary Appendix).
Immunogenicity
We assessed serum samples at baseline and at 
28 and 180 days after injection. We performed the 
enzyme-linked immunosorbent assay (ELISA) for 
ZEBOV-glycoprotein–specific antibodies using the 
homologous Zaire–Kikwit strain glycoprotein 
(following the standard operating procedure of 
the U.S. Army Medical Research Institute for 
Infectious Diseases [SOP AP-03-35-00]) or inac-
tivated whole virions of the Zaire–Guéckédou 
strain. The relative amounts of ZEBOV-glycopro-
tein–specific antibodies were reported as end-
point titers or as geometric mean concentrations 
of arbitrary ELISA units per milliliter. Neutral-
izing antibodies were detected with the use of 
VSV pseudovirions expressing the luciferase re-
porter gene complemented by glycoprotein from 
the ZEBOV 95 Kikwit strain, as described previ-
ously,18 or infectious ZEBOV isolate Mayinga. 
(For detailed descriptions, see the Methods sec-
tion in the Supplementary Appendix.)
Statistical Analysis
We determined the frequencies of all adverse 
events according to study center and dose group. 
Categorical variables are described with counts 
and percentages, and continuous variables with 
means and standard deviations or medians and 
interquartile ranges for skewed variables. Anti-
body responses are reported as the geometric 
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mean titer or geometric mean concentration with 
95% confidence intervals. We obtained reverse 
cumulative distributions by plotting for each 
possible value of the titer the proportion of par-
ticipants with a titer greater than this value. We 
used Fisher’s exact test, the Mann–Whitney test, 
and the Kruskal–Wallis test or Spearman’s cor-
relation coefficient to calculate intergroup as-
sociations. We compared geometric mean titers 
or concentrations, seropositivity rates, and sero-
response rates between days 0 and 28 using 
Wilcoxon’s test for paired data and McNemar’s 
test. Antibody persistence and correlation among 
assays were assessed by comparing geometric 
mean titers or concentrations at 28 days with 
those at 180 days with the use of Wilcoxon’s test 
for paired data and Spearman’s correlation co-
efficient, respectively.
The blinding was broken after the 3-month 
visit for all Geneva participants. For the Geneva 
trial, immunogenicity analyses were conducted 
according to both intention-to-treat and per-
protocol principles. In the intention-to-treat 
analyses, all participants who received an injec-
tion were included; per-protocol analyses exclud-
ed participants who might have been exposed to 
Ebola virus or who had received an unplanned 
additional vaccine dose after the initial adminis-
tration of vaccine. In the absence of significant 
differences (see the Supplementary Appendix), 
results of the intention-to-treat analysis are re-
ported. All statistical testing was two-sided with 
an alpha level of 0.05. The statistical analysis 
plans are provided in the study protocol at 
NEJM.org.
R esult s
Study Populations
A total of 158 participants received either vac-
cine (150 participants) or placebo (8 participants) 
in the three dose-escalation studies from No-
vember 17, 2014, through January 19, 2015, and 
in the Geneva randomized, controlled trial from 
November 10, 2014, through December 9, 2014, 
before a safety-driven study hold and subsequent 
resumption of vaccination with a lower dose 
(3 million PFU) (Fig. S4 in the Supplementary 
Appendix). The study populations are described 
in Table 1, and in Table S2 in the Supplementary 
Appendix. In Geneva, the run-in participants 
and those who underwent randomization were 
compared for baseline characteristics and adverse-
event outcomes. In the absence of significant 
differences, pooled results are reported. Vaccine 
was administered in doses as follows: 300,000 
PFU in 20 participants, 3 million PFU in 49 par-
ticipants, 10 million PFUs in 35 participants, 
20 million PFU in 30 participants, and 50 million 
PFU in 16 participants. All but 3 participants 
were followed for at least 6 months (Fig. S4 in 
the Supplementary Appendix).
Nine participants in Geneva were excluded 
from the 6-month per-protocol analyses: eight 
had been deployed to Ebola-affected countries and 
reported potential exposure to Ebola virus, and 
one had received an extra-study booster dose at 
3 months while in Guinea. The results reported 
here are from interim databases for ongoing trials.
Safety
Serious Adverse Events
There were no serious adverse events associated 
with the vaccine. Seven hospitalizations oc-
curred in Lambaréné for malaria (4 patients), 
appendicitis (1 patient), gastritis (1 patient), and 
bleeding after tooth extraction (1 patient).
Acute Reactogenicity
Solicited and unsolicited adverse events were 
frequent. Of the 158 participants, 145 (92%) had 
at least one adverse event, with the majority of 
events reported as mild or moderate. Grade 3 
symptoms were reported in 4 of 40 participants 
(10%) in Kilifi, 2 of 20 (10%) in Hamburg, and 
11 of 51 (22%) in Geneva; none were reported in 
Lambaréné. Local reactogenicity was common 
but generally mild. Most adverse events appeared 
early (median, 1 day; interquartile range, <24 
hours to 1 day), subsided rapidly (median, 1 day; 
interquartile range, <24 hours to 1 day), and 
were alleviated with the use of acetaminophen 
or nonsteroidal antiinflammatory drugs as need-
ed. The incidence and intensity of the events 
varied according to both the dose and the study 
site: objective fever was reported in 5 of 20 par-
ticipants (25%) in Hamburg, 13 of 51 (25%) in 
Geneva, 12 of 40 (30%) in Kilifi, and 5 of 39 
(13%) in Lambaréné. At a given dose, such as 
3 million PFU, inflammatory reactions were 
more frequently reported in hospitalized partici-
pants in Hamburg than in Lambaréné. A de-
tailed list of adverse events is provided in Table 
S3 in the Supplementary Appendix.
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Biologic Monitoring
Hematologic changes were observed in all par-
ticipants who were monitored during the first 
days after vaccination (Table S4 in the Supple-
mentary Appendix). In Lambaréné, transient 
leukocytopenia was observed in 12 of 20 partici-
pants (60%) receiving 300,000 PFU and in 8 of 
19 participants (42%) receiving 3 million PFU; 
lymphocytopenia was observed in 2 of 19 partici-
pants (11%) in the group receiving 3 million PFU.
In Hamburg, an asymptomatic decrease in the 
number of circulating lymphocytes was observed 
1 day after vaccination in all participants and 
resolved by day 2 (P<0.01 for all comparisons 
between screening and day 1). The decrease was 
unrelated to dose, reactogenicity, or substantial 
viremia, indicating biologic activity even at a 
dose of 3 million PFU. Among the 51 partici-
pants in Geneva, 36 (71%) had a decreased num-
ber of circulating lymphocytes on day 1, and 27 
(53%) had a decreased number of neutrophils on 
day 3, with rapid resolution of both conditions 
(Table S4 in the Supplementary Appendix). 
Monocytosis on day 3 and a transient reduction 
in platelets were also observed. Liver-function 
and creatinine levels remained unchanged.
Viremia and Viral Shedding
Low levels of rVSV-ZEBOV RNA were identified 
in plasma on RT-PCR assay on days 1 to 3 in 
most participants who were tested (Fig. 1, and 
Table S5 in the Supplementary Appendix). Par-
ticipants with positive results for rVSV on PCR 
assay ranged from 8 of 20 (40%) among Lam-
baréné vaccinees immunized with 300,000 PFU 
to 46 of 51 (90%) among Geneva vaccinees. In 
Lambaréné, 18 of 19 participants (95%) who 
received a dose of 3 million PFU had detectable 
viremia on day 1 or 2; 15 of 19 participants 
(79%) had complete resolution by day 7. The 
same pattern was observed in Kilifi, where 35 of 
40 participants (88%) had values that were below 
the detection level by day 7. In Hamburg, all 
participants who received doses of 3 million and 
20 million PFU who were monitored daily until 
day 7 had detectable viremia, with peaks on day 
2 or 3 and complete resolution by day 5.
All but 11 plasma specimens from all studies 
were negative by day 7, and infectious virus was 
not recovered from any blood specimen tested. 
In the Geneva study, there was no correlation 
between peak viremia and vaccine dose, age, sex, T
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frequency or intensity of adverse events, or lym-
phocytopenia. Viral RNA was not detected in 
saliva or urine samples at any site; occasional 
oral lesions were all negative for rVSV on PCR 
assay.
Arthritis
In Geneva, 11 of 51 participants (22%) with no 
previous history of joint disease had an onset of 
arthralgia a median of 11 days (interquartile 
range, 9 to 13) after injection; 8 participants had 
received 10 million PFU and 3 had received 50 
million PFU. These participants presented with 
asymmetric involvement of a median of 2 (range, 
1 to 4) peripheral joints, with swelling on physi-
cal examination and, as seen on ultrasonogra-
phy, tenosynovitis or bursitis in at least 1 joint 
(Table S6 in the Supplementary Appendix). Three 
participants had axial involvement; of these, 1 had 
evidence of arthritis on MRI. Thus, arthritis was 
confirmed in 9 of 11 participants. Pain was often 
migratory and generally mild. Among partici-
pants in whom pain was prolonged, the median 
duration was 8 days (interquartile range, 4 to 87), 
and pain generally became less intense and 
more intermittent after the first week. The func-
tional effect of the arthritis was moderate, with 
a median score of 2.5 (interquartile range, 1.8 to 
3.3) on the Routine Assessment of Patient Index 
Data 3 (RAPID3),19 on a scale ranging from 1 to 
10, with higher values indicating a greater sever-
ity. Results also indicated low inflammatory dis-
ease activity, with a median score of 1.8 (inter-
quartile range, 1.7 to 2.0) on the disease activity 
score in 44 joints (DAS44),20 on a scale ranging 
from 0 to 10, with higher values indicating more 
active disease. Post-vaccination elevations in au-
toantibodies were not observed. A knee arthro-
centesis in 1 participant yielded 40 ml of fluid 
with 7190 leukocytes per milliliter (80% mono-
cytes) and rVSV at 1200 copies per milliliter on 
PCR assay, whereas synovial viral and bacterial 
cultures and rVSV viremia remained negative. 
No association between the presence of arthritis 
and vaccine dose, age, sex, earlier arthralgia, or 
peak viremia was observed among the Geneva 
participants. Suspected, self-limited relapses, one 
with mild arthralgia and the other with mild 
arthritis, occurred in 2 participants after a pro-
longed pain-free interval (Table S6 in the Supple-
mentary Appendix). At the 6-month visit, 10 of 
11 participants with arthritis were symptom-free. 
Two self-limited cases of arthritis were observed, 
one each in Hamburg and Kilifi. (Details re-
garding these cases are provided in the Supple-
mentary Appendix.)
Skin Lesions
Among the 11 participants in Geneva who had 
arthritis, a mild maculopapular rash mainly on 
the limbs developed in 3 participants between 
days 7 and 9 and lasted 7 to 15 days (Fig. 2A, 
subpanel a). The rash was associated with a few 
tender vesicles on fingers or toes (Fig. 2B, sub-
panel d). Histologic analysis of one papule re-
vealed a dermal T-lymphocytic infiltrate (Fig. 2A, 
subpanels b and c). Vesicular lesions reflected 
subepidermal dermatitis with necrotic keratino-
cytes (Fig. 2B, subpanel d) containing abundant 
VSV antigens (Fig. 2B, subpanel f).21 Among the 
3 participants with rash, rVSV was identified on 
RT-PCR in all 3 up to day 17, and infectious rVSV 
was isolated from a specimen with the highest 
RNA level 9 days after immunization (Fig. 2C). 
Concomitantly obtained plasma samples re-
mained negative, showing local replication. At 
other VEBCON trial sites, investigators screened 
participants for rVSV-associated dermatologic 
findings, but none were observed.
ZEBOV-Glycoprotein–Specific Antibody 
Responses
Serum antibodies induced by rVSV-ZEBOV were 
assessed with the use of four distinct assays. 
Baseline antibody levels were generally low, with 
outliers. Low-level baseline seropositivity was 
identified in 12 of 23 participants (52%) in Lam-
baréné and occasionally at other sites (Table 2 
and Fig. 3A, and Tables S7 through S11 in the 
Supplementary Appendix).
Four weeks after immunization, ZEBOV-glyco-
protein–specific antibodies were detected on 
ELISA in all vaccinees with similar anti-glyco-
protein geometric mean titers and distribution, 
as seen on reverse cumulative distribution curves 
(Fig. 3E). The lowest dose (300,000 PFU) was 
immunogenic in Lambaréné, although among 
participants receiving this dose, a low response 
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rate was more frequent than among those re-
ceiving higher doses (Fig. 3A through 3D). Rates 
of seropositivity (0 to 53%) and titers were lower 
on whole-virion ELISA (Fig. 3B, and Table S9 and 
Fig. S5 in the Supplementary Appendix), which 
identified baseline antibodies reacting with nu-
cleocapsid or matrix proteins, but not glycopro-
tein, in samples from Lambaréné (Fig. S6 in the 
Supplementary Appendix).
On pseudovirion neutralization assay as-
sessing the 50% serum neutralization capacity 
(PsVNA50), neutralizing antibodies were absent 
at baseline (including among participants in 
Lambaréné) but were elicited at day 28 in 107 of 
126 vaccinees (85%) (Fig. 3C, and Table S10 in 
the Supplementary Appendix). With the use of 
infectious ZEBOV particles, low-level neutraliz-
ing antibodies (≥1:8) were detected at baseline in 
6 of 20 participants (30%) in Hamburg, 7 of 40 
(18%) in Kilifi, and 10 of 38 (26%) in Lambaréné 
(Fig. 3D, and Table S10 in the Supplementary 
Appendix). The two assays showed significant 
increases in neutralizing antibodies after any 
dose of rVSV-ZEBOV (Tables S10 and S11 in the 
Supplementary Appendix).
Figure 1. Plasma Recombinant Vesicular Stomatitis 
 Virus (rVSV) Viremia in the Four Study Cohorts.
The presence of rVSV viremia was assessed with the 
use of quantitative reverse-transcriptase–polymerase-
chain-reaction (RT-PCR) assays (TaqMan) of total RNA 
derived from plasma. The viral load is expressed as 
log10 rVSV RNA copies per milliliter. Each measurement 
included no-template and standard controls. The shaded 
area indicates values that are below the limit of quanti-
fication (≤100 copies per milliliter of RNA in Lambaréné, 
Kilifi, and Geneva and ≤200 copies per milliliter in Ham-
burg). Panels A and B show the plasma viral load through 
day 28 for the two Hamburg cohorts that received doses 
of 3 million or 20 million plaque-forming units (PFU), 
with daily sampling from day 1 to day 7. Panels C and 
D show individual viremia patterns in two cohorts that 
received doses of 300,000 or 3 million PFU, as moni-
tored in Lambaréné. Plasma was analyzed between day 0 
and day 2 and on day 7 in all participants. Panels E and 
F show the plasma viral load on days 0, 1, 3, and 7 among 
participants in Kilifi who received doses of 3 million or 
20 million PFU. Panels G and H show rVSV RNA copy 
numbers on days 0, 1, 3, and 7 in participants in Gene-
va who received vaccine doses of 10 million or 50 mil-
lion PFU.
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Despite strong correlations between day 28 
antibody titers on glycoprotein ELISA and on 
PsVNA50 (Fig. S7 in the Supplementary Appen-
dix), significant differences were observed. In 
the randomized, controlled Geneva study, a dose 
of 50 million PFU elicited titers of glycoprotein-
binding antibodies that were similar to those 
elicited by 10 million PFU, with geometric mean 
titers of 1780 (95% confidence interval [CI], 
1048 to 3022) and 1064 (95% CI, 757 to 1495), 
respectively, but significantly higher PsVNA50 
antibody titers, with geometric mean titers of 273 
(95% CI, 157 to 475) and 99 (95% CI, 62 to 159) 
(P = 0.02). The influence of increasing doses on 
the distribution of neutralizing antibodies was 
confirmed on reverse cumulative distribution 
(Fig. 3F) and correlation analyses (Tables S12 and 
S13 and Fig. S8 in the Supplementary Appendix). 
Thus, higher doses of rVSV-ZEBOV elicited simi-
lar glycoprotein-binding titers but higher neutral-
izing-antibody titers. Across the four study sites, 
a weak but significant correlation between vac-
cine dose and the level of glycoprotein-binding 
antibodies was observed (Fig. S8 in the Supple-
mentary Appendix).
Six months after immunization, glycoprotein-
Figure 2. Vaccine-Induced Maculopapular and Vesicular Dermatitis.
Panel A shows maculopapular lesions on the thigh of a participant (subpanel a). Histologic analysis of one papule 
revealed a dermal T-lymphocytic infiltrate (subpanel b, hematoxylin and eosin staining) characterized mainly by 
CD3+ T cells (subpanel c). Panel B shows vesicular lesions on the plantar side of the toes of a participant (subpanel 
d). Histologic analysis shows subepidermal vesicular dermatitis with vacuolar degeneration, keratinocyte necrosis, 
acute and lymphohistiocytic inflammation and fibrin (subpanel e, hematoxylin and eosin staining). Higher-power 
magnification of the same area shows abundant immunostaining of rVSV antigens associated with cellular debris 
and inflammatory infiltrate (subpanel f, immunoalkaline phosphatase technique21 with the use of a mouse antibody 
against VSV and Naphthol fast red substrate). Panel C shows the isolation of rVSV-ZEBOV, with a cytopathic effect 
induced on Vero E6 cells after culture with control medium (subpanel g) or a swabbed skin vesicle (subpanels h and 
i) observed by means of either phase-contrast light microscopy (subpanels g and h) or after immunostaining (sub-
panel i) for VSV matrix protein (green, rVSV-ZEBOV–infected cells, with Evans blue counterstaining; red, noninfect-
ed cells).
A Maculopapular rash B Vesicular dermatitis C rVSV isolation
a
b
c
d
e
f
g
h
i
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Study Site 
and Dose
No. of 
Participants GMT
GMT Ratio 
of Day 180 
vs. Day 28 P Value for GMT Seropositivity†
P Value  
for Seropositivity
Day 0 
vs. 28
Day 0 
vs. 180
Day 28 
vs. 180
Day 0 
vs. 28
Day 0 
vs. 180
no. (%)
Geneva
Placebo
Day 0  8   25.0 0
Day 28  8   25.0 NA 0 NA
Day 180  8   25.0 1.00 NA NA 0 NA
10 million PFU
Day 0 34   33.9 8 (24)
Day 28 34 1064.2 <0.001 34 (100) <0.001
Day 180 33 1634.0 1.59 <0.001 0.004 33 (100) <0.001
50 million PFU
Day 0 13   36.3 5 (38)
Day 28 13 1780.1 0.002 13 (100) 0.008
Day 180 15 1837.9 1.05 0.002 0.89 15 (100) 0.008
Lambaréné
300,000 PFU
Day 0 20   42.0 <0.001 11 (55) 0.004
Day 28 20 1055.6 20 (100)
Day 180 16  712.9 0.89 0.001 0.61 15 (94) 0.03
3 million PFU
Day 0 19   38.7 <0.001 3 (19) <0.001
Day 28 19 2570.9 19 (100)
Day 180 17 1359.2 0.59 <0.001 0.04 17 (100) <0.001
Kilifi
3 million PFU
Day 0 20   33.0 3 (15)
Day 28 20 1492.9 <0.001 20 (100) <0.001
Day 180 20 1392.6 0.93 <0.001 0.79 20 (100) <0.001
20 million PFU
Day 0  0 NA
Day 28  0 NA NA NA NA
Day 180 20 1600.0 NA NA NA 20 (100) NA
Hamburg
3 million PFU
Day 0 10   25.0 0.006 0 0.002
Day 28 10 1392.9 10 (100)
Day 180  9  903.9 0.71 0.009 0.40 9 (100) 0.004
20 million PFU
Day 0 10   30.8 0.006 2 (20) 0.008
Day 28 10 1969.8 10 (100)
Day 180 10 1600.0 0.81 0.006 0.37 10 (100) 0.008
*  An expanded version of this table with additional data and 95% confidence intervals is provided in Table S7 in the Supplementary Appendix. 
NA denotes not applicable.
†  Seropositivity was defined as an end-point titer of 50 or more.
Table 2. End-Point Geometric Mean Titer (GMT) and Seropositivity Rate, According to Study Site, Dose of rVSV-ZEBOV, and Timing  
of Visit.*
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binding antibodies persisted in all participants, 
across doses and study sites, without a signifi-
cant decline in geometric mean titers (Table 2 
and Fig. 3A, and Table S7 in the Supplementary 
Appendix). Antibody titers more than doubled 
after day 28 in 41 of 126 participants (33%) and 
reached significantly higher geometric mean ti-
ters of 10 million PFU at 180 days in Geneva 
recipients (geometric mean ratio of 180-day titer 
to 28-day titer, 1.59; 95% CI, 1.21 to 2.09; 
P = 0.004). The deployment of 8 participants to 
Ebola-affected countries during the Ebola out-
break was not reflected by an increase in anti-
body titers.
On the basis of whole-virion ELISA, we also 
observed sustained antibody titers, which de-
clined significantly only in Geneva recipients of 
50 million PFU (geometric mean ratio of 180-day 
titer to 28-day titer, 0.54; 95% CI, 0.32 to 0.91; 
P = 0.03) (Fig. 3B, and Table S9 in the Supple-
mentary Appendix). Neutralizing antibodies that 
were detected with infectious ZEBOV particles 
also persisted through 180 days in 45 of 73 par-
ticipants (62%) (Fig. 3D, and Table S11 in the 
Supplementary Appendix). In contrast, antibod-
ies that were measured by means of the pseudo-
virion neutralization assay were up to 94% lower 
at 180 days than at 28 days and persisted in only 
28 of 120 participants (23%) (Table S10 and 
Fig. 3C in the Supplementary Appendix). Never-
theless, a strong correlation between antibody 
titers on PsVNA50 and on glycoprotein ELISA 
persisted at 180 days, which suggests a rapid de-
cline in initially modest PsVNA50 titers (Fig. S7 
in the Supplementary Appendix).
Discussion
The Zaire-variant candidate vaccine rVSV-ZEBOV 
expresses a viral surface glycoprotein that has 
immunogenic potential after a single dose for 
populations at risk for Ebola virus disease, as well 
as possibly for postexposure prophylaxis.4,7,17,22 
It is a replication-competent chimeric virus for 
which human-safety data were limited to a sin-
gle postexposure case report21 at the time of the 
initiation of these studies. We describe the safety 
and immunogenicity results for rVSV-ZEBOV in 
African and European populations, collected in 
four harmonized, ongoing trials, including three 
dose-escalating trials and one randomized, con-
trolled trial.
Acute inflammatory symptoms were expected 
after immunization with rVSV-ZEBOV. The fre-
quency and intensity of such symptoms were 
study-dependent. At a vaccine dose of 3 million 
PFU, objective fever was reported in 20 to 30% 
of vaccinees in Hamburg and Kilifi but in only 
10% in Lambaréné. An influence of dose on 
adverse events was noted between a dose of 
300,000 and 3 million PFU in Lambaréné but not 
between higher doses at other sites. It is likely 
that the early onset, short duration, and respon-
siveness to symptomatic treatment of these 
symptoms will facilitate acceptance of the vac-
cine, but vaccine-induced fever should be antici-
pated if rVSV-ZEBOV is administered to contacts 
of patients infected with Ebola virus disease.
Levels of rVSV RNA were transiently detected 
in early blood samples, suggesting that innate 
responses, especially those involving the type I 
interferon pathway, help to limit viral replica-
tion.23-26 Viral seeding of joints and skin, mostly 
identified in the Geneva cohort, was unexpected. 
It showed that viral dissemination and replica-
tion can occur and persist for up to 2 to 3 weeks 
after immunization — in other words, that early 
Figure 3 (facing page). Glycoprotein Antibody Titers, 
According to Vaccine Dose, Study Site, and Assay.
Individual antibody titers were assessed at baseline 
and at 28 and 180 days after vaccination in 158 partici-
pants, according to study site and dose group. The vac-
cine dose (in PFU) is indicated for each site in Panels A 
through D; the shaded areas indicate negative titers. 
The numbers of samples tested are provided in Figure 
S4 in the Supplementary Appendix. Antibodies were 
measured on enzyme-linked immunosorbent assay 
(ELISA) against the homologous glycoprotein (GP) of 
the Zaire–Kikwit strain (ZEBOV, Panel A) or inactivated 
whole virions of the Zaire–Guéckédou strain (Panel B). 
Results are expressed as end-point titers (Panel A) or 
the geometric mean concentration of arbitrary ELISA 
units (AEU) per milliliter (Panel B). Neutralizing anti-
bodies were detected with the use of rVSV pseudo-
virion neutralization assay assessing the 50% serum 
neutralization capacity (PsVNA50) complemented by 
homologous glycoprotein (Panel C) or with infectious 
ZEBOV isolate Mayinga (Panel D). Geometric mean ti-
ters and 95% confidence intervals are shown for each 
study site, dose group, and time point. The results of 
glycoprotein ELISA (Panel E) and pseudoneutralization 
(Panel F) at 28 days were expressed as the reciprocal 
of the highest dilution showing a positive result. The 
curves represent the distribution of individual antibody 
titers in each cohort. The dashed curves in Panel E in-
dicate baseline titers.
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innate responses may not always be sufficient 
for complete viral control. Replication appeared 
to be restricted to permissive tissues: viral RNA 
remained below detection in plasma and periph-
eral-blood mononuclear cells, and replicating 
virus was retrieved only from skin vesicles. Skin 
vesicles in livestock infected with VSV or foot-
and-mouth virus occur at similar locations, re-
flecting the relative resistance of keratinocytes 
to type I interferon.27 The pattern of rVSV-ZEBOV 
replication in humans thus may be defined by 
the permissiveness of rVSV replication.28,29
In the Geneva cohort, arthritis was confirmed 
in 9 of 51 participants (18%) and suspected in 
another 2. Two cases were reported among 60 
participants in Hamburg and Kilifi (3%), albeit 
at a lower intensity and of shorter duration than 
in Geneva. Possible mechanisms of virus-induced 
arthritis include autoimmunity, lytic effects of 
infected synovial cells, and the deposition of im-
mune complexes. The induction of autoimmu-
nity is not supported by the rapid onset (<2 weeks) 
and the lack of vaccine-induced pathogenic anti-
bodies. We cannot rule out immune-complex 
deposition, but the detection of rVSV RNA in sy-
novial fluid showed the seeding of rVSV-ZEBOV 
into joints. Since arthralgia or arthritis is not 
elicited by VSV and was not reported with other 
rVSV constructs that have been tested to date, 
the pathophysiology of the chimeric rVSV-ZEBOV 
vaccine may include features attributable to both 
its VSV and ZEBOV glycoprotein components. 
Although pain may be prolonged and relapse 
may occur, the prognosis of viral vaccine–induced 
arthritides is considered favorable on the basis 
of experience with rubella vaccination.30 Accord-
ingly, the VEBCON data and safety monitoring 
board concluded on January 1, 2015, that the tri-
als could proceed as originally planned (including 
doses up to 100 million PFU) once informed-
consent forms were updated. Of the 13 partici-
pants with arthritis, 10 were symptom-free at 
the 6-month visit, which suggests a favorable 
long-term prognosis for these vaccine-induced 
arthritides.
The rVSV-ZEBOV vaccine generated glycopro-
tein-binding antibodies in all participants at any 
dose, showing its immunogenicity in humans, 
in accordance with the field efficacy subsequently 
reported from Guinea.31 Doses containing as 
few as 300,000 PFU may be sufficient to elicit 
glycoprotein-binding antibodies. Preexisting anti-
bodies to ZEBOV nucleocapsid or matrix proteins 
conferred no advantage for the induction of 
glycoprotein-specific responses (Fig. S6 in the 
Supplementary Appendix). Neutralizing antibod-
ies were also generated in most participants, and 
a dose–response effect was shown. Despite simi-
lar glycoprotein-binding antibody titers, higher 
vaccine doses elicited higher titers of neutraliz-
ing antibodies. Since the relative roles of neu-
tralizing and glycoprotein-binding antibodies in 
protection against Ebola virus disease are un-
known, we cannot conclude whether higher vac-
cine doses are required for the most effective 
protection. A comparison of anti–glycoprotein-
antibody titers detected in this study (in the 
Hamburg cohort receiving 20 million PFU) with 
those reported with a chimpanzee adenovirus 
vector32 revealed similar values. This finding sug-
gests that the two vaccines that are currently 
undergoing testing in West Africa may induce 
humoral responses of the same order of mag-
nitude.
Antibody persistence is expected to play a 
critical role in the duration of protection induced 
by rVSV-ZEBOV, a factor that cannot currently be 
informed by efficacy studies. The persistence of 
glycoprotein-binding antibody titers through 
180 days is promising and suggests that a single 
dose of rVSV-ZEBOV may be sufficient for early31 
and possibly longer-term protection. In the ab-
sence of established correlates of protection, the 
importance of the low titers and rapid decline of 
antibodies capable of inhibiting cell entry, as 
measured by means of the PsVNA50 assay, is 
uncertain.
These studies have contributed to the dose-
selection process performed by the vaccine manu-
facturers and have raised the awareness of inves-
tigators, members of institutional review boards, 
and regulators about the specific adverse events 
to be expected with the use of the rVSV-ZEBOV 
vaccine. They have also resulted in the introduc-
tion of safety-driven changes in the protocols for 
the ongoing phase 2 and 3 studies.
In conclusion, in four rapidly implemented, 
parallel phase 1 studies that included in-depth 
safety investigations, the rVSV-ZEBOV vaccine 
was found to be reactogenic but immunogenic at 
doses ranging from 300,000 to 50 million PFU 
in African and European volunteers, with higher 
titers of antibodies at higher doses. The viral 
dissemination in skin and joints that was ob-
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served in some participants appears to be self-
limited, which has resulted in a favorable risk–
benefit balance, given the possible protection31 
offered by this vaccine in the potential control of 
outbreaks of Ebola virus disease.
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